In contrast to the high frequency of TP53 mutations observed in many human cancers of adults, mutations of TP53 have been reported in less than 2% of neuroblastomas at diagnosis and 15% at relapse (Carr-Wilkinson et al., 2010; Tweddle et al., 2003). The gene discussed is TP53; the disease is cancer.